Abstract: The present invention relates generally to &agr;-L-iduronidase and to genetic sequences encoding same. More particularly, the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides which encodes or are complementary to a sequence which encodes a mammalian &agr;-L-iduronidase or fragment or derivative thereof and to the recombinant enzyme encoded thereby. These molecules are useful in the investigation, diagnosis and treatment of subjects suspected of or suffering from &agr;-L-iduronidase deficiency.
Type:
Grant
Filed:
August 30, 1999
Date of Patent:
May 29, 2001
Assignee:
Women's and Children's Hospital
Inventors:
Hamish Steel Scott, Donald Stewart Anson, Annette Marie Orsborn, Paul Victor Nelson, Peter Roy Clements, Charles Phillip Morris, John Joseph Hopwood
Abstract: The present invention relates generally to mammalian sulphamidase and to genetic sequences encoding same and to the use of these in the investigation, diagnosis and treatment of subjects suspected of or suffering from sulphamidase deficiency.
Type:
Grant
Filed:
August 9, 1999
Date of Patent:
March 13, 2001
Assignee:
Women's and Children's Hospital
Inventors:
John Joseph Hopwood, Hamish Steele Scott, Craig Geoffrey Freeman, Charles Phillip Morris, Lianne Cheryl Blanch, Xiao Hui Guo
Abstract: The present invention provides a highly glycosylated iduronate-2-sulfatase enzyme comprising an iduronate-2-sulfatase polypeptide with at least 5 kilodalton (kDa) more sugar than iduronate-2-sulfatase purified from a natural source, e.g. human liver. The present invention also provides an enzymatically active polypeptide fragment or variant of such a highly glycosylated iduronate-2-sulfatase. The present invention further provides an isolated nucleic acid encoding iduronate-2-sulfatase, as well as an expression vector, a host cell and a method for producing the present highly glycosylated iduronate-2-sulfatase enzyme.
Type:
Grant
Filed:
February 12, 1999
Date of Patent:
November 28, 2000
Assignee:
Women's and Children's Hospital
Inventors:
Peter J. Wilson, Charles Phillip Morris, Donald Stewart Anson, Teresa Occhiodoro, Julie Bielicki, Peter Roy Clements, John Joseph Hopwood
Abstract: The present invention relates generally to .alpha.-L-iduronidase and to genetic sequences encoding same. More particularly, the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides which encodes or are complementary to a sequence which encodes a mammalian .alpha.-L-iduronidase or fragment or derivative thereof and to the recombinant enzyme encoded thereby. These molecules are useful in the investigation, diagnosis and treatment of subjects suspected of or suffering from .alpha.-L-iduronidase deficiency.
Type:
Grant
Filed:
November 13, 1998
Date of Patent:
November 21, 2000
Assignee:
Women's and Children's Hospital
Inventors:
Hamish Steele Scott, Donald Stewart Anson, Annette Marie Orsborn, Paul Victor Nelson, Peter Roy Clements, Charles Phillip Morris, John Joseph Hopwood
Abstract: The present invention relates generally to mammalian sulphamidase and to genetic sequences encoding same and to the use of these in the investigation, diagnosis and treatment of subjects suspected of or suffering from sulphamidase deficiency.
Type:
Grant
Filed:
June 13, 1997
Date of Patent:
October 26, 1999
Assignee:
Women's and Children Hospital
Inventors:
John Joseph Hopwood, Hamish Steele Scott, Craig Geoffrey Freeman, Charles Phillip Morris, Lianne Cheryl Blanch, Xiao Hui Guo
Abstract: The present invention provides a highly glycosylated iduronate-2-sulfatase enzyme comprising an iduronate-2-sulfatase polypeptide with at least 5 kilodalton (kDa) more sugar than iduronate-2-sulfatase purified from a natural source, e.g. human liver. The present invention also provides an enzymatically active polypeptide fragment or variant of such a highly glycosylated iduronate-2-sulfatase. The present intention further provides an isolated nucleic acid encoding iduronate-2-sulfatase, as well as an expression vector, a host cell and a method for producing the present highly glycosylated iduronate-2-sulfatase enzyme.
Type:
Grant
Filed:
November 28, 1994
Date of Patent:
August 3, 1999
Assignee:
Women's and Children's Hospital
Inventors:
Peter J. Wilson, Charles Phillip Morris, Donald Stewart Anson, Teresa Occhiodoro, Julie Bielicki, Peter Roy Clements, John Joseph Hopwood
Abstract: The present invention relates generally to mammalian sulphamidase and to genetic sequences encoding same and to the use of these in the investigation, diagnosis and treatment of subjects suspected of or suffering from sulphamidase deficiency.
Type:
Grant
Filed:
April 19, 1995
Date of Patent:
January 26, 1999
Assignee:
Women's and Children's Hospital
Inventors:
John Joseph Hopwood, Hamish Steele Scott, Craig Geoffrey Freeman, Charles Phillip Morris, Liane Cheryl Blanch, Xiao-Nui Guo
Abstract: The present invention provides a highly glycosylated iduronate-2-sulfatase enzyme comprising an iduronate-2-sulfatase polypeptide with at least 5 kilodalton (kDa) more sugar than iduronate-2-sulfatase purified from a natural source, e.g. human liver. The present invention also provides an enzymatically active polypeptide fragment or variant of such a highly glycosylated iduronate-2-sulfatase. The present invention further provides an isolated nucleic acid encoding iduronate-2-sulfatase, as well as an expression vector, a host cell and a method for producing the present highly glycosylated iduronate-2-sulfatase enzyme.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
August 25, 1998
Assignee:
Women's and Children's Hospital
Inventors:
Peter J. Wilson, Charles Phillip Morris, Donald Stewart Anson, Teresa Occhiodoro, Julie Bielicki, Peter Roy Clements, John Joseph Hopwood
Abstract: The present invention provides a method of stimulating macrophage, neutrophil and/or monocyte function in a subject. The method involves the administration of an effective amount of a free fatty acid having a 18-24 carbon chain length with 2-6 double bonds. Preferred polyunsaturated fatty acids are 20:4(n-6), 20:3(n-6), 20:5(n-3), 22:6(n-3), 19:2(n-6), 18:3.gamma.(n-6), 23:4(n-6) and 24:4(n-6).
Type:
Grant
Filed:
May 28, 1996
Date of Patent:
June 16, 1998
Assignees:
Peptide Technology Limited, Women's and Childrens Hospital Adelaide
Inventors:
Antonio Ferrante, Alfred Poulos, Deborah A. Rathjen
Abstract: Methods for treating melanoma or a disease caused by bacteria, fungi, Chlamydia, Mycoplasma, Rickettsia or Plasmodium falciparum are disclosed wherein a fatty acid having a carbon length up to 30 carbon atoms and two or more double and/or triple bonds, derivatives or oxidation products thereof is administered.
Type:
Grant
Filed:
March 14, 1994
Date of Patent:
February 18, 1997
Assignee:
Women's and Children's Hospital Adelaide
Inventors:
Antonio Ferrante, Alfred Poulos, Lakshmi M. Kumaratilake, Brenton S. Robinson